HopeStage
Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
More filters: keywords, city, remote
1326studies shown
Showing 1-12 of 1,326
Drug study icon
RecruitingNCT05511363

KarXT for Schizophrenia

What is this study about?

A short description of this study's objective has not yet been verified by HopeStage.

In France
SchizophreniaMedication studyAges 55–90
Countries
France, United States, United Kingdom, + 10 others
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Drug study icon
RecruitingNCT06887192

ML-007C-MA for Schizophrenia

What is this study about?

A short description of this study's objective has not yet been verified by HopeStage.

In France
SchizophreniaMedication studyAges 55–90
Countries
France, United States, Canada, + 12 others
Sponsor
MapLight Therapeutics
Drug study icon
RecruitingNCT06929273

Long-term safety of KarXT in bipolarity type I

What is this study about?

This extension study evaluates the long-term safety and tolerability of KarXT for mania or mania with mixed features in people living with bipolarity type I.

In France
BipolarityMedicationAges 18–65
Countries
France, United States, Australia, + 17 others
Sponsor
Bristol-Myers SquibbPharmaceutical company
Drug study icon
RecruitingNCT06585787

KarXT for Schizophrenia

What is this study about?

A short description of this study's objective has not yet been verified by HopeStage.

In France
SchizophreniaMedication studyAges 55–90
Countries
France, United States, Belgium, + 21 others
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Drug study icon
RecruitingNCT07140913

KarXT for manic episodes in bipolarity type I

What is this study about?

A short description of this study's objective has not yet been verified by HopeStage.

Location not clearly listed
BipolarityMedication studyAges 18–65
Countries
France, United States, Argentina, + 10 others
Sponsor
Bristol-Myers SquibbPharmaceutical company
Drug study icon
RecruitingNCT07424404

Xanomeline and Trospium Chloride for Schizophrenia

What is this study about?

A short description of this study's objective has not yet been verified by HopeStage.

Location not clearly listed
SchizophreniaMedication studyAges 5–17
Countries
France, United States, Australia, + 7 others
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Drug study icon
RecruitingNCT06159673

ACP-204 in Adults With Alzheimer's Disease Psychosis

What is this study about?

A short description of this study's objective has not yet been verified by HopeStage.

Location not clearly listed
SchizophreniaMedication studyAges 55–95
Countries
France, United States, Brazil, + 9 others
Sponsor
ACADIA Pharmaceuticals Inc.
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.